Skip to main content

Home/ MaRS/ Group items tagged Rafael Hofstein

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Assunta Krehl

Market Morning : July 3, 2009 : Market Lookahead [07-03-09 9:15 AM] - 0 views

watch.bnn.ca/...market-morning-july-3-2009

MaRS Innovation Rafael Hofstein entrepreneurship commercialization healthcare

shared by Assunta Krehl on 05 Aug 09 - No Cached
  • Assunta Krehl on 05 Aug 09
     
    Interview with Dr. Rafael Hofstein about how MaRS Innovation will help to accelerate the pace in turning ideas into meaningful products which in turns help the healthcare system. Dr. Hofstein also talked about the 2 medical products that were brought to market: i) Umbilical Cord Stem Cell Technology ii) Diabetic Wound Healing Technology."
Assunta Krehl

MaRS Discovery District - News - News Releases - 2009 - MaRS Innovation selects diabeti... - 0 views

www.marsdd.com/...cialization-uoft-06302009.html

MaRS Innovation Therapeutics collaboration Rafael Hofstein University of Toronto

shared by Assunta Krehl on 05 Aug 09 - No Cached
  • MaRS Innovation and The University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. 
  • This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally,” said Dr. Rafi Hofstein, President and CEO of MaRS Innovation. 
  • disruptive technology that facilitates continued therapeutic release of NO over a two week period has been developed by Dr. Ping Lee, Professor at the Leslie Dan Faculty of Pharmacy and GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery at U of T.
  • ...4 more annotations...
  • This is one of many new commercilization ventures that will be initiated by MaRS Innovation, our partner in commercialization of research with 13 other academic institutions across the Greater Toronto Area,” said Paul Young, U of T’s Vice-President, Research. “We at U of T are delighted that this innovation from Dr. Lee will be taken to the marketplace to the benefit of society and the economy of Ontario and Canada.” 
  • With the launch of this second commercial opportunity, MaRS Innovation will continue to aggregate the exceptional science of its institutional members by being a one-stop commercialization centre for industry, entrepreneurs and investors. MaRS Innovation is expediting the transformation of the Toronto-based research into a powerful commercialization engine. 
  • “MaRS Innovation is deeply committed to facilitating strategic research collaborations with industry partners, strengthening the innovation capacity of Canadian industry through adoption of new technologies, and launching a new generation of robust, high-growth Canadian companies that will become global market leaders,” added Dr. Hofstein. “We look forward to working closely with all of our institutional members and to continue to jointly announce exciting commercial opportunities.”
  • MaRS Innovation is dedicated to bringing brilliant discoveries to market by converting the outstanding science of its member institutions into outstanding economic results for Canada and the world.
  • Assunta Krehl on 05 Aug 09
     
    MaRS Innovation and The University of Toronto (U of T) announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
1 - 2 of 2
Showing 20▼ items per page